The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study.

Immune Response 52

Immune Response Vaccination Vaccine Trials 52

XTalks

APRIL 7, 2021

The test is intended for the detection of COVID-19 infection, either a recent or previous infection, as detected through an adaptive antibody immune response to SARS-CoV-2. The test involves self-collection of a fingerstick dried blood sample.

Antibody 102

Antibody Immune Response Radiology Marketing 102

XTalks

MARCH 10, 2021

Adaptive Biotechnologies’ T-Detect COVID Test is a next-generation sequencing (NGS) test that can indicate recent or prior infection with SARS-CoV-2 through detection of a T cell immune response to the virus. This is the first T cell test of its kind for the detection of COVID-19 infection.

Protein 98

Protein RNA Antibody Production 98

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. It will be funded by the U.S.

DNA 40

DNA Vaccine Vaccination Immune Response 40

The Pharma Data

MARCH 29, 2022

W911QY-21-9-0001. AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

The Pharma Data

MARCH 25, 2022

The half-life extension more than triples the durability of its action compared to conventional antibodies;(11-13) data from the PROVENT Phase III trial show protection lasting at least six months.(14) W911QY-21-9-0001.

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

The Pharma Data

DECEMBER 23, 2020

The other, 69-70, leads to the loss of two amino acids in the spike protein and seems to help viruses evade the immune response in some immunocompromised patients. Davidoff Department of Neurological Surgery and of radiology at Einstein. In research in South Africa in B.1.1.7,

Research 52

Research Protein Gene Vaccination 52